SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to recent announcements of its advanced GaN and SiC power platforms aimed at next-gen AI data centers and its positioning within NVIDIA's AI ecosystem. The community is actively discussing the immense potential of its technology while simultaneously expressing significant concern over the absence of definitive, revenue-generating contracts amidst anticipation for its earnings call.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results in axial spondyloarthritis, with its drug sonelokimab showing an 81% response rate and potential for disease modification, fueling expectations for a major re-rating and potential short squeeze ahead of its Investor Day.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following ANKTIVA's conditional marketing authorization across 33 European countries and accelerated approval in Saudi Arabia for lung cancer, sparking community excitement over immediate global revenue growth and an anticipated short squeeze, as many view Dr. Patrick Soon-Shiong's immunotherapy platform as an "unstoppable" force in cancer treatment.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is gaining attention following its AI division joining the NVIDIA Inception Program and widespread adoption of its Intents technology for cross-chain integrations. The community is actively discussing its growing user base, recent tokenomics improvements, and its strategic positioning in the evolving AI and blockchain landscape.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is a focal point of investor discussion as the comment period for its critical NOAA deep-sea mining permit application has concluded, fueling strong community conviction that approvals are imminent given the escalating national demand for essential minerals for security and the energy transition.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating US-Iran tensions are a primary catalyst, leading the community to intensely debate the potential for military action and a subsequent surge in oil prices, positioning Exxon Mobil as a key beneficiary. This geopolitical focus, coupled with the company's strong production in regions like Guyana and strategic moves into carbon capture, is driving bullish sentiment despite some concerns about the stock's rapid ascent.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is experiencing a significant surge, driven by extreme cold weather and widespread winter storms across the US, leading to massive heating demand, production disruptions, and historic trading volumes. While many anticipate further gains from continued storage draws, a strong contingent cautions that warmer weather is approaching, highlighting natural gas's well-known volatility and the potential for a swift reversal.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is generating significant buzz as its community actively accumulates the token, driven by speculation around potential ETFs and its perceived status as the next-generation Layer 1 blockchain. Enthusiasts highlight its superior speed and efficiency compared to rivals, with many viewing current price levels as a prime buying opportunity.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing heightened volatility as traders grapple with escalating geopolitical tensions in the Middle East that could impact LNG transit, juxtaposed with uncertain late-winter weather patterns and the complexities of natural gas futures contract rollovers. The community is sharply divided, with bulls betting on a short squeeze driven by supply concerns and growing AI data center demand, while bears emphasize robust production and the leveraged ETF's inherent decay.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly awaits its imminent BLA resubmission for deramiocel, with high expectations for a significant rally and potential buyout given its "life-saving" potential for Duchenne Muscular Dystrophy patients. Further discussions highlight optimism for accelerated approval, especially amidst evolving FDA policies and widespread calls for regulatory clarity in the rare disease space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Qiagen (NYSE:QGEN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Qiagen from a "hold" rating to a "buy" rating in a research note on Saturday...

Traders Purchase High Volume of Put Options on Qiagen (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Traders bought 8,189 put options on the stock. This is an increase of 460...

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the...

Futures Fall As AI Selloff Resumes

Futures Fall As AI Selloff Resumes US equity futures woke up after President's Day and chose to resume their selloff (after a modest bounce on Monday's holiday failed to hold) dragged by Tech, as the...

Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Analysts

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been given an average rating of "Hold" by the twelve research firms that are covering the stock, Marketbeat Ratings reports. Eight investment...

Qiagen N.V. $QGEN Shares Sold by Nuance Investments LLC

Nuance Investments LLC lessened its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 60.3% during the third quarter, according to its most recent filing with the Securities & Exchange...

Qiagen Q4 Earnings Call Highlights

Qiagen (NYSE:QGEN) said it closed 2025 with fourth-quarter results that came in above its outlook, while highlighting growth across key product lines and progress on profitability and cash generation...

JPMorgan Chase & Co. Boosts Qiagen (NYSE:QGEN) Price Target to $60.00

JPMorgan Chase & Co. increased their price objective on Qiagen from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Friday...

Citigroup Cuts Qiagen (NYSE:QGEN) Price Target to $55.00

Citigroup cut their target price on shares of Qiagen from $55.40 to $55.00 and set a "neutral" rating for the company in a research note on Friday...

QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down

QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

QGEN
Qiagen NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest QGEN News

QGENQiagen NV